Konkuk University Medical Center Reports Findings in Type 2 Diabetes (Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data): Nutritional and Metabolic Diseases and Conditions – Type 2 Diabetes

2021 DEC 27 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Nutritional and Metabolic Diseases and Conditions - Type 2 Diabetes is the subject of a report. According to news reporting from Seoul, South Korea, by NewsRx journalists, research stated, “Neuropathy is a common chronic complication in type 2 diabetes mellitus (T2DM). Statin and metformin are commonly used medications in T2DM patients, and some studies showed statin- or metformin-induced neuropathy.”

The news correspondents obtained a quote from the research from Konkuk University Medical Center, “To evaluate the incidence of neuropathy among patients with T2DM associated with statin and metformin therapies. Korean Health Insurance Review and Assessment national patient sample data from 2016 and 2017 were used. Patients with T2DM and no complications were divided into statin/metformin/statin + metformin users and non-users. Neuropathy incidence was defined by International Statistical Classification of Diseases and Related Health Problems, 10 revision codes and concomitant prescriptions for anticonvulsants or antidepressants. Logistic regression analyses were conducted to examine the associations between statin/metformin/statin + metformin therapies and the incidence of neuropathy. Propensity score (PS) matching was performed on the basis of age, sex and comorbidities. Overall, 34964 and 35887 patients with T2DM and no complications were included in the Korean Health Insurance Review and Assessment national patient sample datasets from 2016 and 2017, respectively. Statin therapy was associated with increased risks of neuropathy in 2016 and 2017 [PS-matched odds ratio (OR) = 1.22, 95% confidence interval (CI): 1.08-1.38; PS-matched OR = 1.17, 95%CI: 1.03-1.33, respectively]. Metformin therapy was associated with reduced risks of neuropathy in 2016 and 2017 (PS-matched OR = 0.30, 95%CI: 0.21-0.42; PS-matched OR = 0.44, 95%CI: 0.32-0.60, respectively). Combined statin + metformin therapy was not significantly associated with neuropathy in 2016 or 2017 (PS-matched OR = 0.85, 95%CI: 0.61-1.19; PS-matched OR = 0.95, 95%CI: 0.66-1.38, respectively).”

According to the news reporters, the research concluded: “Statin therapy was associated with enhanced risk of new-onset neuropathy in patients with T2DM, but metformin therapy showed the opposite association.”

This research has been peer-reviewed.

For more information on this research see: Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data. World Journal of Clinical Cases, 2021;9(33):10198-10207. World Journal of Clinical Cases can be contacted at: Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, Ca, United States.

Our news journalists report that additional information may be obtained by contacting Se Hee Kim, Dept. of Internal Medicine, Konkuk University Medical Center, Seoul KS013, South Korea. Additional authors for this research include Hong Ki Min, Jong Han Choi, Kyomin Choi, Hae-Rim Kim and Sang-Heon Lee.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.12998/wjcc.v9.i33.10198. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the World Journal of Clinical Cases is: Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, Ca, United States.

(Our reports deliver fact-based news of research and discoveries from around the world.)